|
1. |
miR-128 can inhibit proliferation of glioma cells through one of its targets, E2F3a. |
|
2. |
report confirms significant mRNA overexpression of KIF14 and E2F3 together in a large cohort of retinoblastoma tumors |
|
3. |
A significant elevation in expression of E2F3 in oral squamous cell carcinoma cells was seen in carbon and neon-irradiated cells. |
|
4. |
E2F3 modulates Aurora-A mRNA expression during the cell cycle. |
|
5. |
E2F3 gain is associated with the late stage of retinoblastoma. |
|
6. |
Expression of E2F3 was lowest in early-stage tumors and highest in metastatic tissue. Expression profiling of miRNAs in WT showed that expression of each measured member of the Oncomir-1 family was highest in WT relative to other kidney tumor subtypes |
|
7. |
Genes involved in the E2F3 pathway are associated with chemotherapy sensitivity among ER- tumors. The mutant p53 signature and expression of ER-related genes were associated with lower sensitivity to chemotherapy in ER+ breast tumors only. |
|
8. |
Inactivation of the retinoblastoma pathway occurs in bladder tumors with 6p22 amplification. |
|
9. |
E2F3 contributes to ataxia telangiectasia mutated (ATM) kinase-dependent p53 phosphorylation and apoptosis in cells expressing E1A. |
|
10. |
requirement of E2F3 for BCR/ABL leukemogenesis |
|
11. |
Study demonstrates the strength of E2F3 as a potential marker for discriminating benign and malignant disease, addressing the current limitations of serum PSA measurements. |
|
12. |
Data suggest that the physical interaction of TFE3 and E2F3 facilitates transcriptional activation of the p68 gene and provides strong evidence for the specificity of E2F function. |
|
13. |
results suggest that DEK and E2F3 are potential targets of 6p gains in retinoblastoma |
|
14. |
E2F3 is overexpressed in 55-70% of squamous cell carcinomas and 79% of adenocarcinomas of the lung. In addition very high level expression of nuclear E2F3 is found in almost all small cell lung cancers analysed. |
|
15. |
In bladder cancer, the E2F3 gene is associated with overexpression of its encoded mRNA transcripts and high levels of E2F3 expression. |
|
16. |
We conclude that E2F3 is frequently amplified and overexpressed in invasively growing bladder cancer (stage pT1-4). E2F3 expression appears to provide a growth advantage to tumor cells by activating cell proliferation in a subset of bladder tumors. |
|
17. |
determination of interaction with RYBP and YY1 |
|
18. |
E2F3 levels have a critical role in modifying cellular proliferation rate in human bladder and prostate cancer. |
|
19. |
E2F1, E2F2, and E2F3 directly bind the promoter of the mir-17-92 cluster, activating its transcription. miR-20a from the mir-17-92 cluster in turn modulates the translation of E2F2 and E2F3, suggesting an autoregulatory feedback loop. |
|
20. |
E2F3 mRNA and protein are overexpressed in retinoblastoma. |